content: <html>
  
  <head>
  
  
  
  
  
  </head>
  
  <body lang="EN-US" style="text-justify-trim: punctuation">
  
  <div style="font-family:Times New Roman;">
  
  <div style="border:none;border-top:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
  STATES<br>
  SECURITIES AND EXCHANGE COMMISSION<br>
  </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
  REPORT<br>
  Pursuant to Section&nbsp;13 OR 15(d)&nbsp;of The Securities Exchange Act of
  1934</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report
  (Date of earliest event reported):&nbsp; <b>April&nbsp;30, 2008</b></font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Sepracor
  Inc.</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of
  Registrant as Specified in its Charter)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-19410</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">22-2536587</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other
    Juris-<br>
    diction of Incorporation</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission<br>
    File Number)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer<br>
    Identification No.)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">84
    Waterford Drive<br>
    Marlborough, MA</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;"><br>
    01752</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal
    Executive Offices)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
  telephone number, including area code:&nbsp; <b>(508)
  481-6700</b></font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or
  Former Address, if Changed Since Last Report)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425
  under the Securities Act (17 CFR 230.425)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12
  under the Exchange Act (17 CFR 240.14a-12)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant
  to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="1" face="Times New Roman" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant
  to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='',FILE='C:\JMS\tbamidi\08-13159-1\task2907763\13159-1-ba.htm',USER='tbamidi',CD='Apr 30 19:14 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div style="font-family:Times New Roman;">
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.01&#160; Entry into a Material Definitive Agreement.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Settlement and License Agreement</font></i></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>
  
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;30, 2008,
  Sepracor Inc. (the &#147;Company&#148;) entered into a Settlement and License Agreement
  (the &#147; Agreement&#148;) with Breath Limited (&#147;Breath&#148;) to resolve the patent
  litigation involving the Company&#146;s XOPENEX</font><sup><font face="Symbol">&#210;</font></sup> brand inhalation solutions products (1.23
  mg/3 mL, 0.63 mg/3 mL and 0.31 mg/3 mL) (the &#147;Sepracor Products&#148;).&#160; The parties will promptly file a dismissal
  without prejudice in the United States District Court for the District of
  Massachusetts that will conclude the litigation. As part of the settlement, the
  parties granted mutual releases related to the subject matter of the
  litigation.</p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Settlement and License
  Agreement permits Breath to sell its generic versions of the Sepracor Products
  (the &#147;Breath Products&#148;) in the United States under the terms of an exclusive
  license from the Company commencing on August&nbsp;20, 2012 (subject to earlier
  commencement of the license under certain circumstances as provided in the
  agreement).&#160; Upon launch, Breath would
  pay Sepracor a double digit royalty on gross profits generated from the sales
  of generic versions of the Sepracor Products.&#160;
  Under the Settlement and License Agreement, Breath agrees not to sell any
  of the products covered by the Company&#146;s patents that are the subject of the
  license before the date on which the license commences.&#160; Further, the Settlement and License Agreement
  contains provisions requiring each of the Company and Breath to indemnify the
  other party under certain circumstances.</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>
  
  <p align="left" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">T</font>he </font>Settlement and License Agreement is a
  final settlement of the Breath litigation.&#160;
  The settlement with Breath does not end all disputes related to the
  Sepracor Products, as litigation against Dey L.P. and Barr Laboratories,&nbsp;Inc.
  remains pending.&#160; In compliance with U.S. law, the Settlement and License Agreement and the
  Supply Agreement (discussed below) will be submitted to the U.S. Federal Trade
  Commission and Department of Justice and are subject to their review.</p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Supply Agreement</font></i></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;30, 2008, the
  Company and Breath also entered into a Supply Agreement (the &#147;Supply
  Agreement&#148;) whereby, effective August&nbsp;20, 2012, the Company will
  exclusively supply theSepracor Products (1.23 mg/3 mL, 0.63 mg/3 mL and 0.31
  mg/3 mL) to Breath, under the Company&#146;s NDA, for a period of 180 days (the
  &#147;Initial Term&#148;) and on a non-exclusive basis for up to an additional two and
  one-half year period thereafter. In addition to the royalties described above,
  Breath will pay the Company on a cost plus margin basis for supply of the
  levalbuterol HCl products.&#160; Both the
  exclusive license under the Settlement Agreement and the exclusive supply
  obligations under the Supply Agreement could become effective prior to August&nbsp;20,
  2012, if a third party launches a generic version of those dosages of the
  Sepracor Products or if the parties otherwise mutually agree.&#160; The Supply Agreement contains provisions
  requiring each of the Company and Breath to indemnify the other party under
  certain circumstances.&#160; The Supply
  Agreement also contains standard provisions regarding termination for cause and
  convenience, including either parties right to terminate at any time after the
  Initial Term upon nine (9)&nbsp;months written notice.</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman">&nbsp;</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Forward-Looking
  Statements</font></i></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:0in;"><font size="2" face="Times New Roman">&nbsp;</font></p>
  
  <p align="left" style="margin:0in 0in .0001pt;text-align:left;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Report on Form&nbsp;8-K
  contains forward-looking statements that involve risks and uncertainties,
  including statements regarding the timing of introduction of generic versions
  of Sepracor Products, the amount and timing of royalty payments, and the timing
  of the effectiveness of the exclusive license and exclusive supply obligations
  under the Settlement and License Agreement and the Supply Agreement,
  respectively.&#160; Certain factors could
  cause actual results to differ materially from those indicated by such
  forward-looking statements, including the timing of a third party launch of a
  generic version of the Sepracor Products, the sales of the Breath Products, and
  those factors detailed in the Company&#146;s annual report on Form&nbsp;10-K for the
  year ended December&nbsp;31, 2007 filed with the Securities and Exchange
  Commission.</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\tbamidi\08-13159-1\task2907763\13159-1-ba.htm',USER='tbamidi',CD='Apr 30 19:14 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, the
  statements in this Report on Form&nbsp;8-K represent the Company&#146;s expectations
  and beliefs as of the date of this Report. Subsequent events and developments
  may cause these expectations and beliefs to change. However, while the Company
  may elect to update these forward-looking statements at some point in the
  future, unless required by applicable law, it specifically disclaims any
  obligation to do so.&#160; These
  forward-looking statements should not be relied upon as representing the
  Company&#146;s expectations or beliefs as of any date subsequent to the date of this
  Report on Form&nbsp;8-K.</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\tbamidi\08-13159-1\task2907763\13159-1-ba.htm',USER='tbamidi',CD='Apr 30 19:14 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURES</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="52%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sepracor Inc.</font></p>
    </td>
   </tr>
   <tr>
    <td width="47%" valign="top" style="padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="52%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr height="14" style="height:.15in;">
    <td width="47%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;1, 2008</font></p>
    </td>
    <td width="6%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
    </td>
    <td width="45%" height="14" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;height:.15in;padding:0in .7pt 0in .7pt;width:45.56%;">
    <p style="margin:0in 0in 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Andrew I. Koven</font></p>
    </td>
   </tr>
   <tr height="14" style="height:.15in;">
    <td width="47%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="6%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>
    </td>
    <td width="45%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:45.56%;">
    <p style="margin:0in 0in 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Andrew I. Koven</font></p>
    </td>
   </tr>
   <tr height="14" style="height:.15in;">
    <td width="47%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:47.78%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="6%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:6.64%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: </font></p>
    </td>
    <td width="45%" height="14" valign="top" style="height:.15in;padding:0in .7pt 0in .7pt;width:45.56%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive Vice President, General Counsel and
    Corporate Secretary</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  <!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\tbamidi\08-13159-1\task2907763\13159-1-ba.htm',USER='tbamidi',CD='Apr 30 19:14 2008' -->
  
  
  </body>
  
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "a08-13159_18k.htm", "description": "8-K", "secsgml_size_bytes": 28566}]
metadata_filer: {"company-data": {"conformed-name": "SEPRACOR INC /DE/", "cik": "0000877357", "assigned-sic": "2834", "irs-number": "222536587", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19410", "film-number": "08791956"}, "business-address": {"street1": "84 WATERFORD DRIVE", "city": "MARLBOROUGH", "state": "MA", "zip": "01757", "phone": "5084816700"}, "mail-address": {"street1": "84 WATERFORD DRIVE", "city": "MARLBOROUGH", "state": "MA", "zip": "01752"}}
text: UNITED
  STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT
  REPORT
  Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
  1934
  Date of Report
  (Date of earliest event reported):
  April 30, 2008
  Sepracor
  Inc.
  (Exact Name of
  Registrant as Specified in its Charter)
  Delaware
  0-19410
  22-2536587
  (State or Other
    Juris-
  diction of Incorporation
  (Commission
  File Number)
  (IRS Employer
  Identification No.)
  84
    Waterford Drive
  Marlborough, MA
  01752
  (Address of Principal
    Executive Offices)
  (Zip Code)
  Registrant's
  telephone number, including area code:
  (508)
  481-6700
  (Former Name or
  Former Address, if Changed Since Last Report)
  Check the appropriate box below if the Form 8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions (
  see
  General Instruction A.2. below):
  o
  Written communications pursuant to Rule 425
  under the Securities Act (17 CFR 230.425)
  o
  Soliciting material pursuant to Rule 14a-12
  under the Exchange Act (17 CFR 240.14a-12)
  o
  Pre-commencement communications pursuant
  to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  o
  Pre-commencement communications pursuant
  to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  Item 1.01  Entry into a Material Definitive Agreement.
  Settlement and License Agreement
  On April 30, 2008,
  Sepracor Inc. (the "Company") entered into a Settlement and License Agreement
  (the " Agreement") with Breath Limited ("Breath") to resolve the patent
  litigation involving the Company's XOPENEX
  Ò
  brand inhalation solutions products (1.23
  mg/3 mL, 0.63 mg/3 mL and 0.31 mg/3 mL) (the "Sepracor Products").  The parties will promptly file a dismissal
  without prejudice in the United States District Court for the District of
  Massachusetts that will conclude the litigation. As part of the settlement, the
  parties granted mutual releases related to the subject matter of the
  litigation.
  The Settlement and License
  Agreement permits Breath to sell its generic versions of the Sepracor Products
  (the "Breath Products") in the United States under the terms of an exclusive
  license from the Company commencing on August 20, 2012 (subject to earlier
  commencement of the license under certain circumstances as provided in the
  agreement).  Upon launch, Breath would
  pay Sepracor a double digit royalty on gross profits generated from the sales
  of generic versions of the Sepracor Products. 
  Under the Settlement and License Agreement, Breath agrees not to sell any
  of the products covered by the Company's patents that are the subject of the
  license before the date on which the license commences.  Further, the Settlement and License Agreement
  contains provisions requiring each of the Company and Breath to indemnify the
  other party under certain circumstances.
  T
  he
  Settlement and License Agreement is a
  final settlement of the Breath litigation. 
  The settlement with Breath does not end all disputes related to the
  Sepracor Products, as litigation against Dey L.P. and Barr Laboratories, Inc.
  remains pending.  In compliance with U.S. law, the Settlement and License Agreement and the
  Supply Agreement (discussed below) will be submitted to the U.S. Federal Trade
  Commission and Department of Justice and are subject to their review.
  Supply Agreement
  On April 30, 2008, the
  Company and Breath also entered into a Supply Agreement (the "Supply
  Agreement") whereby, effective August 20, 2012, the Company will
  exclusively supply theSepracor Products (1.23 mg/3 mL, 0.63 mg/3 mL and 0.31
  mg/3 mL) to Breath, under the Company's NDA, for a period of 180 days (the
  "Initial Term") and on a non-exclusive basis for up to an additional two and
  one-half year period thereafter. In addition to the royalties described above,
  Breath will pay the Company on a cost plus margin basis for supply of the
  levalbuterol HCl products.  Both the
  exclusive license under the Settlement Agreement and the exclusive supply
  obligations under the Supply Agreement could become effective prior to August 20,
  2012, if a third party launches a generic version of those dosages of the
  Sepracor Products or if the parties otherwise mutually agree.  The Supply Agreement contains provisions
  requiring each of the Company and Breath to indemnify the other party under
  certain circumstances.  The Supply
  Agreement also contains standard provisions regarding termination for cause and
  convenience, including either parties right to terminate at any time after the
  Initial Term upon nine (9) months written notice.
  Forward-Looking
  Statements
  This Report on Form 8-K
  contains forward-looking statements that involve risks and uncertainties,
  including statements regarding the timing of introduction of generic versions
  of Sepracor Products, the amount and timing of royalty payments, and the timing
  of the effectiveness of the exclusive license and exclusive supply obligations
  under the Settlement and License Agreement and the Supply Agreement,
  respectively.  Certain factors could
  cause actual results to differ materially from those indicated by such
  forward-looking statements, including the timing of a third party launch of a
  generic version of the Sepracor Products, the sales of the Breath Products, and
  those factors detailed in the Company's annual report on Form 10-K for the
  year ended December 31, 2007 filed with the Securities and Exchange
  Commission.
  2
  In addition, the
  statements in this Report on Form 8-K represent the Company's expectations
  and beliefs as of the date of this Report. Subsequent events and developments
  may cause these expectations and beliefs to change. However, while the Company
  may elect to update these forward-looking statements at some point in the
  future, unless required by applicable law, it specifically disclaims any
  obligation to do so.  These
  forward-looking statements should not be relied upon as representing the
  Company's expectations or beliefs as of any date subsequent to the date of this
  Report on Form 8-K.
  3
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  Sepracor Inc.
  Date: May 1, 2008
  By:
  /s/ Andrew I. Koven
  Name:
  Andrew I. Koven
  Title:
  Executive Vice President, General Counsel and
    Corporate Secretary
  4